A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)

Inclusion Criteria:

• Adults aged ≥ 40 years with COPD and chronic bronchitis

• Current or ex-smokers (history ≥ 10 pack years).

• Post-bronchodilator FEV1 <60% of the subject predicted normal value and FEV1/FVCratio < 0.7.

• At least, one moderate or severe COPD exacerbation in previous year.

• CAT score ≥ 10

• Subjects on regular maintenance triple therapy for at least 12 months prior toscreening and receiving regular maintenance triple therapy for at least 3 monthsprior to screening visit

Exclusion Criteria:

• Subjects with current asthma.

• Subjects with moderate or severe COPD exacerbation 4 weeks prior to study entry andrandomization.

• Subjects with known α-1 antitrypsin deficiency as the underlying cause of COPD.

• Subjects with COPD emphysema or mixed phenotypes.

• Subjects with known respiratory disorders other than COPD.

• Subjects with active cancer or a history of lung cancer with full recovery less than 1 year after completing cancer therapy.

• Subjects under Roflumilast treatment within 6 months before study entry.

• Subjects with a diagnosis of depression, generalised anxiety disorder, suicidalideation.

• Subjects with clinically significant cardiovascular.

• Subjects with a significant neurological disease.

• Subjects with clinically significant laboratory abnormalities.

• Subjects with moderate or severe hepatic impairment